ReviewLeukemia2002
STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.
Review in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Anticancer drugs: How to select small molecule combinations?Trends in pharmacological sciences · 2024Review
- My battle with cancer. Part 1.Oncoscience · 2024Review
- Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.PloS one · 2019Article
- Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.Oncology letters · 2017Article
- Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Oncotarget · 2015Article
- HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Oncotarget · 2015Article
- Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.Oncotarget · 2014Article
- Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.Cancer biology & therapy · 2014Article
- Selective anti-cancer agents as anti-aging drugs.Cancer biology & therapy · 2013Article
- First steps in experimental cancer evolution.Evolutionary applications · 2013Article
- Article
- Evolutionary dynamics of two related malignant plasma cell lines.Cell cycle (Georgetown, Tex.) · 2010Article
- Use of oncolytic viruses for the eradication of drug-resistant cancer cells.Journal of the Royal Society, Interface · 2009Article
- Drug resistance in cancer: principles of emergence and prevention.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Kinase inhibitors translate lab discoveries into exciting new cures for cancers.Indian journal of pediatrics · 2004Review
- Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.International journal of hematology · 2004Review
- Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.Oncogene · 2003Review
- Tissue-selective therapy of cancer.British journal of cancer · 2003Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seemingly disappointing, the Bcr-Abl kinase inhibitor STI-571 shares an 'unfortunate' characteristic with conventional cancer drugs: the development of drug resistance. I argue that the resistance must develop even faster to STI-571 than to conventional drugs, because STI-571 is so effective. This is predictable, but is it inevitable? And how do mechanisms of resistance in relapse depend on a degree of remission. In addition to mutation rate and number of tumor cells, one additional factor determines relapse vs. 'extinction' of the leukemia cell population.
Indexed as
Identifiers
11960334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.